0001589150 false 09-30 0001589150 2022-03-17 2022-03-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 17, 2022

REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

Commission File No. 333-191725

  

4700 Spring Street, St 304, La MesaCalifornia 91942

(Address of Principal Executive Offices)

(619722 5505

(Issuer’s telephone number)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which registered
  None  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  1  

 

Item 5.03 Amendments to Articles of Incorporation

On March 17, 2022 Regen Biopharma, Inc. (the “Company”) amended its Certificate of Incorporation increasing its authorized common shares from 4, 800,000,000 with a par value of $0.0001 to 5,800,000,000 with a par value of $0.0001. As of March 17, 2022 the Company has 5,800,000,000, common shares authorized at a par value of $0.0001 and 800,000,000 total preferred shares authorized at a par value of $0.0001.

On March 17, 2022 the Company amended the authorized shares of the Company’s Series A Preferred stock and Series M Preferred stock to be 540,000,000 shares of Series A Preferred stock , $0.0001 par value, and 60,000,000 shares of Series M Preferred Stock, $0.0001 par value.

  2  

 


SIGNATURE  

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  REGEN BIOPHARMA, INC.
   
Dated: March 18, 2022 By: /s/ David Koos

 

  3  

 

 

Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Regen Biopharma (PK) Charts.
Regen Biopharma (PK) (USOTC:RGBP)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Regen Biopharma (PK) Charts.